Sometimes it’s not what you do but how.
Chances are you know someone who has had prostate cancer.
It’s one of the most common forms of the disease and, when diagnosed late, one of the deadliest.
But researchers at The University of Newcastle have identified a treatment that could improve survival rates by up to 30 per cent.
They haven’t done it by creating a new drug or therapy.
They’ve done it by looking at which treatment regime is most effective.
During Australia’s biggest-ever cancer trial, subjects were randomly allocated either an additional 12 months of testosterone suppression therapy – on top of the standard six months – or no further treatment.
After 10 years the results showed a clear difference: the longer period of treatment worked better, producing those significantly higher survival rates.
What’s more, lead researcher Jim Denham says it resulted in a 40 per cent reduction in cancer spreading to other parts of the body.
“We also found that that men who received the 18 months of treatment did not experience more side effects or impaired quality of life factors than those who received the six months of hormone treatment,” Professor Denham says.
“Around 17,000 Australian men each year are diagnosed with prostate cancer and we are constantly looking at ways to beat this disease.”
The information in this article should not be considered medical advice. Please see your medical professional for information tailored to your personal circumstances.
Research to improve cancer treatment is only possible if we support our universities. To keep Australia clever, please sign the petition below.